Head-to-head evidence
Gemigliptin vs Trelagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Gemigliptin · Zemiglo
Developed by LG Chem
NCT01787396 · Phase 3 · completed
This was a randomized, quadruple-blind trial (n=433) with three arms: gemigliptin plus metformin, gemigliptin alone (with a matching metformin placebo), and metformin alone (with a matching gemigliptin placebo). The primary endpoint, HbA1c change at 24 weeks, favored the combination over either monotherapy.
Trelagliptin · Zafatek
Developed by Takeda Pharmaceutical Company
NCT03940183 · Phase 3 · completed
The trial randomized 254 participants to trelagliptin or placebo and used quadruple blinding. Its primary endpoint was the surrogate measure of change in HbA1c at week 24, but results were not posted, so whether the comparison favored trelagliptin is unknown.
Next expected readout: December 2026 · NCT07073768 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gemigliptin's landscape · Trelagliptin's landscape